You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News and reporting on colorectal cancer.
Although the benefit seen in the CAVE study needs Phase III confirmation, the analysis showed that plasma ctDNA testing may help identify best responders.
The Phase II study will assess the antibody-drug conjugate patritumab deruxtecan for previously treated colorectal cancer patients expressing varying levels of HER3.
HalioDx's Immunoscore test, which measures host immune response at the tumor site, will be used to select patients for the trial.
The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.
The company said proceeds will accelerate the ongoing FDA registrational study of its blood-based colorectal cancer screening test and further its extended pipeline.
The firm said its genetic tests for breast, prostate, and colorectal cancers and melanoma assess a patient's personal cancer risks and guide personalized prevention.
The company, which uses fruit fly "avatars" to screen drugs, will be collaborating with London IVD Co-operative and Genomics England to test their technology in GI cancer patients.
The researchers said their new study supports the clinical utility of their test, which combines genomic and drug screening analyses of organoids to guide cancer treatment.
The updated guidelines now also highlight the use of PCR and next-generation sequencing to determine microsatellite instability.
The recently renamed company will use the project to develop a new version of its next-generation sequencing assay for cancer mutational analysis.